346 Translational program of the phase II MEDITREME trial: identification of prognostic factors for response to durvalumab and tremelimumab in combination with FOLFOX in metastatic colorectal cancer

• Francois Ghiringhelli,
• Emeric Limagne,
• Marion Thibaudin,
• Caroline Truntzer,
• Olivier Adotevi,
• Caroline Laheurte,
• Elise Ballot,
• Jean-David Fumet

Affiliations

Francois Ghiringhelli

Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France

Emeric Limagne

Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France

Marion Thibaudin

Transfer Biology Cancer Platform, Centre Georges-Francois Leclerc, Dijon, France

Caroline Truntzer

Department of Medical Oncology, Centre Georges François Leclerc, Dijon, France

Olivier Adotevi

INSERM UMR1098 RIGHT Interactions hôte-greffon-tumeur – Ingénierie Cellulaire et Génique, Besancon, Franche-Comté, France

Caroline Laheurte

INSERM UMR 1098, Besançon, France

Elise Ballot

Cancer Biology Transfer Platform, Centre Georges-François Leclerc, Dijon, France

Jean-David Fumet

1Anticancer Center Georges François Leclerc, Dijon, France